Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

insulin

insulin is a insulin receptor agonist.

NMPA: clinical trials
Patents linked 20
Pipeline programs 82
News articles 0
Drug details — insulin
Class
—
Route
—
Patents
20
Programs
82
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

insulin is a insulin receptor agonist.

Key facts

INN insulin
Mechanism Insulin receptor agonist
Target Insulin receptor

Mechanism of action

Insulin receptor agonist

Primary target: Insulin receptor

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Search pipeline
  1. Alogliptin and insulin Phase 3 · Takeda · Diabetes Mellitus
  2. CSII (Insulin Pump) plus DAFNE Phase 3 · United Therapeutics Europe · Type 1 Diabetes
  3. Dapagliflozin 10 mg Phase 3 · AstraZeneca · Diabetes Mellitus, Non-Insulin-Dependent
  4. Dasiglucagon 4 mg/ml Phase 3 · Zealand Pharma · Children with congenital hyperinsulinism
  5. Faster-acting insulin aspart Phase 3 · Novo Nordisk A/S · Diabetes
  6. G-Pen Phase 3 · Universal Integrated · Insulin Hypoglycemia
  7. G-Pen Phase 3 · Xeris Biopharma Holdings · Insulin Hypoglycemia
  8. Human Insulin Inhalation Powder Phase 3 · Eli Lilly and · Diabetes Mellitus

Related & competitor drugs

Browse all drugs
  1. insulin aspart Alimentary tract and metabolism (A10)
  2. insulin aspart protamine recombinant Insulin receptor agonist
  3. insulin aspart recombinant Insulin receptor agonist
  4. insulin degludec Alimentary tract and metabolism (A10)
  5. insulin detemir Alimentary tract and metabolism (A10)
  6. insulin detemir recombinant Insulin receptor agonist

Related patents

Browse patents

  1. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12226437

    Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord mesenchymal stem cell expressing IGF1R and method for obtaining multipotent umbilical cord mesenchymal stem cell

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11974989

    Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11859020

    Insulin like growth factor binding protein bioactive peptide fragments

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11844867

    Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11833136

    Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

    Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2023183767

    MÉTHODES ET COMPOSITIONS POUR AUGMENTER LA SENSIBILITÉ À L'INSULINE

    Expires Wed Sep 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11666637

    Insulin-loaded metal-organic frameworks

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. WO 2023076144

    MÉTHODES ET COMPOSITIONS DESTINÉES À AMÉLIORER LA PRODUCTION ET LA SÉCRÉTION D'INSULINE

    Expires Wed Apr 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11602556

    Insulin mimotopes and methods of using the same

    Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11555055

    Peptide inhibitors of insulin-degrading enzyme

    Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11529373

    Method for enhancing expression of insulin like growth factor 1 receptor in mesenchymal stem cell, method for obtaining mesenchymal stem cell, and method for treating brain tissue damage

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11524987

    Highly purified recombinant human insulin (RHI) API and methods of producing the same

    Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. CA 3213326

    METHODES ET COMPOSITIONS POUR AMELIORER LA PRODUCTION ET LA SECRETION D'INSULINE

    Expires Wed Oct 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11446360

    High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same

    Expires Mon Sep 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11066670

    Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11028061

    Modulators of myocyte lipid accumulation and insulin resistance and methods of use thereof

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10980749

    Therapeutic preparation comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10952993

    Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10660918

    Method for enhancing insulin like growth factor 1 receptor expression of mesenchymal stem cell, method for isolating mesenchymal stem cell, and use of mesenchymal stem cell

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is insulin?

insulin is a insulin receptor agonist.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.